Ann Hematol: Potential risk factors for the development of immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children

Patients with immune thrombocytopenia (ITP) are at risk of developing systemic lupus erythematosus (SLE) in the futu.

Patients with immune thrombocytopenia (ITP) are at risk of developing systemic lupus erythematosus (SLE) in the futu.

The study was a retrospective case-control stu.

Table 1: Clinical manifestations of SLE group and primary ITP group with I.

Table 2: Platelet and megakaryocyte counts between the SLE group with ITP and the primary ITP group

Table 2: Platelet and megakaryocyte counts between the SLE group with ITP and primary ITP group Table 2: Platelet and megakaryocyte counts between the SLE group with ITP and primary ITP group

Table 3: Multivariate analysis of potential risk factors from ITP to S.

Table 3: Multivariate analysis of potential risk factors from ITP to S.

 

The median time to progression from ITP to SLE was 35 [IQR 15, 575] mont.

The median time to progression from ITP to SLE was 35 [IQR 15, 575] mont.

In conclusion, we conducted the first retrospective case-control study of 50 children with ITP who developed SLE and 100 children with primary ITP who did not develop SLE to explore potential risk factors for developing S.

Therefore, studies recommend close follow-up for at least 3 years in pediatric ITP patients and up to 10 years in children with multiple risk factors to monitor the risk of developing S.

Original source:

Original source:

Song,.

Song,.
, Zhang,.
, Li,.
et .
Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case–control study in Chinese childr.
Ann Hematol (202
https:// d.

org/11007/s00277-022-04836- et .

Ann Hematol commentedhere